Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:56:37 EDT Sun 11 Oct 2026
Enter Symbol
or Name
USA
CA



Q:CORT - CORCEPT THERAPEUTICS INC - https://www.corcept.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
CORT - Q1.5110.00·140.321.0121.19+2.652.2624.275,0629,015118.00  122.34  117.575126.3833  28.660119:54:41Sep 2315 min RT 2¢

Recent Trades - Last 10 of 9015
Time ETExPriceChangeVolume
19:54:41Q120.84742.30741
19:30:06Q121.192.651
19:30:06Q121.192.651
19:30:05Q121.192.651
19:30:05Q121.192.651
17:34:50Q121.192.65126,300
17:26:57Q121.192.651,347
16:15:00Q121.192.651
16:10:03Q121.192.651
16:10:03Q121.192.651

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-09-23 08:00U:CORTNews ReleaseCorcept Announces Planned Leadership Transition
2026-09-18 08:00U:CORTNews ReleaseCorcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli(TM) (Relacorilant)
2026-07-29 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
2026-07-22 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
2026-06-17 16:28U:CORTNews ReleaseCorcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
2026-06-06 16:45U:CORTNews ReleaseCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym(TM)
2026-05-29 16:33U:CORTNews ReleaseCorcept Presents New Data at ASCO 2026: Lifyorli(TM) Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure
2026-05-27 08:00U:CORTNews ReleaseCorcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's Syndrome
2026-04-30 16:05U:CORTNews ReleaseCorcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update
2026-04-30 16:05U:CORTNews ReleaseCorcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis
2026-04-23 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call
2026-04-21 13:09U:CORTNews ReleaseCorcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli(TM) (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026
2026-04-10 16:45U:CORTNews ReleaseCorcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli(TM) (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer
2026-03-28 14:45U:CORTNews ReleaseCorcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
2026-03-25 12:43U:CORTNews ReleaseFDA Approves Corcept's Selective Glucocorticoid Receptor Antagonist Lifyorli(TM) (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer
2026-02-24 16:05U:CORTNews ReleaseCorcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update
2026-02-19 16:00U:CORTNews ReleaseCorcept Provides Update on Patent Dispute with Teva Pharmaceuticals
2026-02-17 16:05U:CORTNews ReleaseCorcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call
2026-01-22 08:00U:CORTNews ReleaseOverall Survival Primary Endpoint Met in Corcept's Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
2025-12-31 08:00U:CORTNews ReleaseCorcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism